InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

InflaRx N.V.NASDAQ: IFRX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of €3.29M fell 49.6% year over year, behind the -27.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 10.9% from the prior quarter. Over 3 fiscal years it compounded at +7.0% a year.

Context

  • Selling, general & admin amounted to 59884.7% of revenue in FY2025, up 48228.0 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 3 analysts of €2.5M (-85.8%) for the fiscal year ending Dec 2026, a slowdown from the -9.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
€3.29M+10.9% QoQ
Last fiscal yearDec 2025
€17.56M-9.1% YoY
LTMMar 2026
€14.24M-27.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.6%-75.7%-26.1 pp
1 year-9.1%-85.8%-76.7 pp
3-year CAGR+7.0%-49.1%-56.0 pp
5-year CAGR+153.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

EUR · from the income statement

Latest · FY2025
17.56M EUR
Year-over-year change
-9.1%
4-year CAGR
+11.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -27.6% is the 7th highest of 9, against a peer median of -0.6%.
  • Selling, general & admin amounts to 48538.7% of revenue for IFRX, versus a peer median of 5541.4%.
IFRX Competitors
Selling, General & Admin for IFRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$35.33M USD-27.9%-11.7%35.5%
IMAImageneBio IncLTM Mar 2026$21.2M USD-9.1%-2.3%—
CNTBConnect Biopharma Holdings LimitedFY2025$20.34M USD+5.8%-0.8%31781.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$20.27M USD+8.2%-0.8%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$17.76M USD+24.8%+12.7%9346.3%
STTKShattuck Labs, Inc.LTM Mar 2026$17.37M USD-6.9%-4.3%1736.5%
KLRSKalaris Therapeutics IncLTM Mar 2026$15.32M USD-41.8%+90.0%—
IFRXInflaRx N.V.LTM Mar 2026€14.24M EUR-27.6%+7.0%48538.7%
CNTXContext Therapeutics Inc.LTM Mar 2026$8.11M USD+9.0%+0.2%—
Peer median (excluding IFRX) —-0.6%-0.8%5541.4%

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0063.09K165.79K29.33K
Cost of Revenue00532.26K3.32M7.27M
Gross Profit00(469.17K)(3.15M)(7.24M)
Gross Margin——-743.7%-1900.8%-24677.9%
Research & Development35.7M37.53M41.02M35.36M25.72M
Selling, General & Admin11.43M14.34M16.12M19.33M17.56M
Operating Expenses47.63M32.24M44.13M49.75M41.02M
Depreciation & Amortization669.43K596.6K567.78K485.11K419.48K
EBITDA(44.94M)(28.84M)(42.06M)(45.55M)(45.16M)
EBITDA Margin——-66674.3%-27476.7%-153976.3%
Operating Income(47.63M)(32.24M)(44.59M)(52.91M)(48.26M)
Operating Margin——-70685.6%-31911.4%-164525.5%
Interest Income109.39K608.68K3.8M3.2M1.77M
Interest Expense24.77K45.25K35.63K20.66K37.69K
Other Income / Expenses2M2.75M1.93M6.85M2.64M
Income Before Tax(45.63M)(29.48M)(42.67M)(46.06M)(45.62M)
Pre-Tax Margin——-67630.7%-27781.8%-155540.2%
Income Tax Expense0005.22K12.28K
Net Income(45.63M)(29.48M)(42.67M)(46.06M)(45.63M)
Net Margin——-67630.7%-27785.0%-155582.1%
EPS (Basic)(1.10)(0.61)(0.78)(0.78)(0.66)
EPS (Diluted)(1.10)(0.61)(0.78)(0.78)(0.66)
Weighted Avg Shares41.63M44.21M54.94M58.92M67.29M
Weighted Avg Shares (Diluted)41.63M44.21M54.94M58.92M67.29M

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.